A randomized controlled study of acupuncture combined with Wuzi Yan zong formula in the treatment of idiopathic oligozoospermia

注册号:

Registration number:

ITMCTR2024000354

最近更新日期:

Date of Last Refreshed on:

2024-09-02

注册时间:

Date of Registration:

2024-09-02

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

针刺联合五子衍宗方治疗特发性少弱精子症的随机对照研究

Public title:

A randomized controlled study of acupuncture combined with Wuzi Yan zong formula in the treatment of idiopathic oligozoospermia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺联合五子衍宗方治疗特发性少弱精子症的随机对照研究

Scientific title:

A randomized controlled study of acupuncture combined with Wuzi Yan zong formula in the treatment of idiopathic oligozoospermia

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

文皓烺

研究负责人:

刘保兴

Applicant:

WenHaolang

Study leader:

LiuBaoxing

申请注册联系人电话:

Applicant telephone:

+8615305046606

研究负责人电话:

Study leader's telephone:

+8613661259625

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

863871527@qq.com

研究负责人电子邮件:

Study leader's E-mail:

liubx66@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区北三环东路11号

研究负责人通讯地址:

北京市朝阳区樱花园东街 2 号

Applicant address:

No. 11, North 3rd Ring East Road, Chaoyang District, Beijing

Study leader's address:

No. 2, Yinghua Yuan East Street, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京中医药大学

Applicant's institution:

Beijing University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2024-KY-136

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

中日友好医院临床研究伦理委员会

Name of the ethic committee:

Ethics Committee for Clinical Research of China-Japan Friendship Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024/5/24 0:00:00

伦理委员会联系人:

崔勇

Contact Name of the ethic committee:

CuiYong

伦理委员会联系地址:

北京市朝阳区樱花园东街 2 号

Contact Address of the ethic committee:

No. 2, Yinghua Yuan East Street, Chaoyang District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

010-84206250

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zryyec@126.com

研究实施负责(组长)单位:

中日友好医院

Primary sponsor:

China-Japan Friendship Hospital

研究实施负责(组长)单位地址:

北京市朝阳区樱花园东街 2 号

Primary sponsor's address:

No. 2, Yinghua Yuan East Street, Chaoyang District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

朝阳区

Country:

China

Province:

Beijing

City:

Chaoyang District

单位(医院):

中日友好医院

具体地址:

北京市朝阳区樱花园东街 2 号

Institution
hospital:

China-Japan Friendship Hospital

Address:

No. 2, Yinghua Yuan East Street, Chaoyang District, Beijing

经费或物资来源:

首都卫生发展科研专项

Source(s) of funding:

Capital Health Development Research Special Fund

研究疾病:

特发性少弱精子症

研究疾病代码:

Target disease:

Idiopathic Oligoasthenospermia

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

验证针刺联合五子衍宗方治疗轻中度特发性少弱精子症(肾虚精亏证)的临床疗效及安全性,形成中医特色治疗方案。

Objectives of Study:

To verify the clinical efficacy and safety of acupuncture combined with Wuzi yan zong formula in the treatment of mild to moderate idiopathic oligoasthenospermia (Kidney Deficiency and Essence Depletion Syndrome) and to develop a Traditional Chinese Medicine characteristic treatment plan.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①符合男性不育症及轻中度特发性少弱精子症诊断标准; ②中医辨证为肾精亏虚证; ③年龄 22-40 岁,性功能正常,定期规律性生活; ④女方生育能力正常; ⑤近 1 月未行改善精子质量的中西医治疗; ⑥同意参加本研究,签署知情同意书。

Inclusion criteria

1. Meets the diagnostic criteria for male infertility and mild to moderate idiopathic oligoasthenospermia. 2. Diagnosed with Kidney Essence Deficiency Syndrome according to Traditional Chinese Medicine differentiation. 3. Aged between 22 and 40 years, with normal sexual function and regular sexual activity. 4. The female partner has normal fertility. 5. Has not received any treatment, either Traditional Chinese Medicine or Western medicine, to improve sperm quality in the past month. 6. Agrees to participate in this study and signs the informed consent form.

排除标准:

①配偶诊断为女性不孕症患者; ②尿道上裂或下裂、抗精子抗体阳性、染色体异常、无精子症、睾丸发育不 良、泌尿生殖系感染、内分泌异常者; ③精索静脉曲张或有附睾、输精管等器质性病变者; ④正在服用改善精子质量的药物或激素、抗肿瘤等影响精子生成药物者; ⑤合并心肝肾和造血系统等严重疾病; ⑥针刺部位有水肿、感染、破溃或皮肤病者; ⑦晕针、惧针、晕血者。

Exclusion criteria:

1. The spouse has been diagnosed with female infertility. 2. Patients with hypospadias or epispadias, positive anti-sperm antibodies, chromosomal abnormalities, azoospermia, testicular dysplasia, urogenital infections, or endocrine disorders. 3. Patients with varicocele or organic lesions of the epididymis, vas deferens, etc. 4. Patients currently taking medications to improve sperm quality or medications that affect sperm production, such as hormones or anti-tumor drugs. 5. Patients with severe diseases affecting the heart, liver, kidneys, or hematopoietic system. 6. Patients with edema, infection, ulceration, or skin diseases at the acupuncture sites. 7. Patients who are prone to fainting, fear needles, or have a tendency to faint at the sight of blood.

研究实施时间:

Study execute time:

From 2024-06-01

To      2026-12-31

征募观察对象时间:

Recruiting time:

From 2024-06-01

To      2026-03-01

干预措施:

Interventions:

组别:

五子衍宗方组

样本量:

50

Group:

Wuzi Yan zong formula group

Sample size:

干预措施:

给予五子衍宗方口服12周治疗。五子衍宗方 药物组成:枸杞子 30g,菟丝子 30g,覆盆子 20g,五味子 5g,车前子 10g 药剂制备:由中日友好医院中药房提供代煎 100ml 汤剂。 服用方法:每日 2 次,每次 100ml,共服用 12 周。

干预措施代码:

Intervention:

Administration of Wuzi Yan zong formula orally for 12 weeks. Composition of Wuzi Yanzong Formula: - Goji Berries (Gouqi Zi) 30g - Dodder Seed (Tusizi) 30g - Raspberry (Fupenzi) 20g - Schisandra (Wuweizi) 5g - Plantain Seed (Cheqianzi) 10g - Preparation of the Decoction: Prepared by the China-Japan Friendship Hospital’s pharmacy, providing a 100ml decoction. - Dosage and Administration: Take 100ml twice daily, for a total of 12 weeks.

Intervention code:

组别:

针刺+五子衍宗方组

样本量:

50

Group:

Acupuncture + Wuzi Yan zong formula group

Sample size:

干预措施:

给予患者为期12周的针刺+口服五子衍宗方治疗。 针刺: 太溪,大钟,三阴交,关元。予以疏密波电针刺激20min,每周2次。 五子衍宗方口服方法同前。

干预措施代码:

Intervention:

Administration of a 12-week treatment combining acupuncture and oral Wuzi Yanzong Formula. - Acupuncture: - Points: Taixi (KI3), Dazhong (KI4), Sanyinjiao (SP6), Guanyuan (CV4) - Electroacupuncture with alternating dense and sparse waves for 20 minutes, twice weekly. - Oral Administration of Wuzi Yanzong Formula: The method of oral administration is the same as previously described.

Intervention code:

样本总量 Total sample size : 100

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

朝阳区

Country:

China

Province:

Beijing

City:

Chaoyang District

单位(医院):

中日友好医院

单位级别:

中央所属医疗机构

Institution/hospital:

China-Japan Friendship Hospital

Level of the institution:

Centrally Affiliated Medical Institutions

测量指标:

Outcomes:

指标中文名:

中医证候积分

指标类型:

次要指标

Outcome:

Traditional Chinese Medicine Syndrome Score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

配偶妊娠率

指标类型:

主要指标

Outcome:

Spouse Pregnancy Rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

精液参数

指标类型:

次要指标

Outcome:

Semen Parameters

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

精液

组织:

Sample Name:

Semen

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 22
Min age years
最大 40
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男性

Male

随机方法(请说明由何人用什么方法产生随机序列):

由数据管理员按照区组随机的方法对患者进行随机分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

Patients will be randomly assigned to groups by the data managers using block randomization methods.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Don't share raw data.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用统一的纸质病例报告表,对所有填写了知情同意书并筛选合格的入组患者,均须认真、详细记录病例报告表中各项数据,勿空项、漏项。两名数据管理员负责数据的录入与核对,使用 Excel 或 EpiData 3.0 建立本研究数据库。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

A standardized paper case report form (CRF) must be used to carefully and thoroughly record all data for each enrolled patient who has signed the informed consent form and passed the screening. No fields should be left blank or omitted. Two data managers will be responsible for data entry and verification, and the research database will be established using either Excel or EpiData 3.0.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above